Navigation Links
At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site
Date:11/24/2014

Baltimore, MD (PRWEB) November 24, 2014

Continental Clinical Solutions, LLC (Continental) focuses on recruiting underrepresented patient populations into clinical trials at its mid-Atlantic late-phase research facility, located in Baltimore, Maryland.

“Continental was created with the idea of closing patient disparities in mind. Clinical trials play a fundamental role in medical advances," said Continental's CEO, Saleh Stevens. "From the Tuskegee syphilis experiment to the immortal cell line of Henrietta Lacks, dubious ethical practices and on-going safety concerns have plagued recruitment in the minority segment for clinical trials in the US and abroad." The exclusion of large patient populations from clinical trials adversely impacts scientific advances.

Almost 40% of registered clinical studies occur in the United States, equaling an approximate 66,700 clinical trials. The number of trials in the US increased by almost 16% since 2013, according to ClinicalTrials.gov, a website dedicated to information on clinical studies registered with the FDA. Despite the increase in studies, the percentage of the US population participating in studies has remained stagnant at 6%.

“When you further distill that 6%, you find minorities in late phase studies are terribly underrepresented. Underrepresentation means missed opportunities to address specific genomics and other criteria that will influence drug efficacy in the specific populations, sentencing future generations to inadequate medical remedies," Stevens added.

Though mistrust is a large obstacle in diversity in recruitment, insurance and cost of care continue to play a role in stymying minority recruitment into trials. Many unapproved treatments have been reserved solely for patients who can afford to pay out of pocket for travel and study-related healthcare needs. Those costs can vary from hundreds to tens of thousands of dollars, according to a report commissioned by the Pharmaceutical Researchers and Manufacturers of America. Previously, many insurers excluded healthcare related to certain phases of clinical trials under "experimental" and "investigational" exclusions in their policies. These exclusions, when triggered, not only denied reimbursement of trial-related healthcare costs, but sometimes resulted in policy cancellation—an untenable circumstance for patients already leery of joining studies.

Beginning January 1, 2014, the Affordable Care Act set forth legislative changes impacting some of the cost issues patients face when considering clinical trials. The resulting federal laws ensured that new health insurance plans cover routine care costs for people taking part in clinical trials. Insurers are no longer permitted to drop coverage because of patient participation in a clinical trial. Maryland, among a few other states, has been ahead of the curve with covering significant costs associated with clinical trials, with legislation dating as far back as 1998.

"With the connectivity that social media platforms afford us, it is incumbent upon us to communicate the changing landscape to patient populations who are left either unaware or out of the study pipeline," Stevens concluded as he reiterated Continental’s commitment to reducing disparities in clinical trial patient populations at its Maryland site.

Continental Clinical Solutions, LLC is a multi-therapeutic dedicated research clinic providing turnkey clinical trial sites for community practitioners in all trial phases, bringing diverse patient populations and industry pharmaceutical companies together. Visit Continental Clinical Solutions at http://www.continentalclinical.com.

Read the full story at http://www.prweb.com/releases/ContinentalClinicalMD/SalehStevens/prweb12323817.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dr. Adrienne C. Scheck, Ph.D. is recognized by Continental Whos Who as a Pinnacle Professional
2. F. David Rollo, MD, Ph.D., FACC, FACNP is recognized by Continental Whos Who as a Pinnacle Professional
3. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
4. Positive Clinical Study Results for BSPs HyperQ Technology
5. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
9. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
10. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
11. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):